양성 전립선 비대증 치료제 시장 보고서(2026년)

Drugs for benign prostatic hypertrophy are used to treat enlarged prostate glands by relaxing the bladder neck muscles and muscle fibers in the prostate, which makes urination easier. This condition is commonly observed in men over the age of 50.

The primary categories of medications for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other drugs. Alpha-blockers, also referred to as blockers or adrenoreceptor antagonists, are a class of pharmaceutical agents that function by inhibiting adrenergic receptors. The various sectors consist of hospital pharmacies, retail pharmacies, and others, and these medications are supplied through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have marginally increased the cost of imported APIs used in the manufacturing of benign prostatic hyperplasia drugs. These impacts are most evident in markets that continue to rely on cross border sourcing for pharmaceutical inputs. Rising tariff related costs have placed mild pressure on production economics and pricing strategies for BPH therapies. This has influenced procurement planning and capacity utilization decisions among manufacturers. However, tariffs are also supporting the expansion of domestic production of BPH drugs, local API manufacturing, and stronger long term supply security.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with a drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for benign prostatic hypertrophy market size has grown steadily in recent years. It will grow from $4.55 billion in 2025 to $4.75 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to aging population growth, long-term alpha blocker usage, hospital-based urology care, availability of oral therapies, improved diagnostic tools.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increase in male life expectancy, rising healthcare access, innovation in combination drugs, expansion of outpatient urology clinics, lifestyle-related risk factors. Major trends in the forecast period include rising demand from aging male population, increased adoption of combination therapies, growth of minimally invasive drug treatments, expansion of generic bph drugs, growing awareness of early diagnosis.

The rising prevalence of prostate diseases is expected to drive the growth of the market for drugs treating benign prostatic hypertrophy (BPH) in the coming years. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ situated just below the bladder. The increase in prostate disease prevalence is largely linked to aging, along with metabolic and inflammatory factors that contribute to conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. Drugs for BPH play a key role in managing and relieving urinary symptoms associated with prostate diseases, offering benefits by reducing prostate enlargement and enhancing urine flow. For example, in August 2024, Cancer Therapy Advisor, a US-based medical information provider, reported that an estimated 299,010 new cases of prostate cancer were expected to be diagnosed in the country in 2024, representing 14.9 percent of all new cancer cases, with slightly over 35,000 deaths projected. Consequently, the growing prevalence of prostate diseases is fueling the expansion of the market for drugs targeting benign prostatic hypertrophy.

Major companies operating in the drugs for benign prostatic hypertrophy market are focusing on developing solutions with technological advancements, such as new medications for both enlarged prostate (benign prostatic hyperplasia, BPH) and erectile dysfunction, to strengthen their competitive position in the market. Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, while erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer primarily involved in paints and coatings, launched Tamsulosin + Tadalafil Capsule to broaden its product portfolio in the pharmaceutical sector, particularly in areas addressing common men's health concerns. This innovative product, Cromax, features a dual-action formulation combining Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, and Tadalafil, which enhances blood flow to the penis to support erections. This combination therapy not only provides a more convenient treatment option for men with both benign prostatic hyperplasia (BPH) and erectile dysfunction but also shows notable improvements in the International Prostate Symptom Score (IPSS).

In September 2025, Medicus Pharma Ltd., a US-based pharmaceutical company, acquired Antev Limited for an undisclosed amount. Through this acquisition, Medicus Pharma intends to strengthen its drugs for benign prostatic hypertrophy (BPH) portfolio by incorporating Antev's established product offerings and regulatory expertise, facilitating the development and commercialization of therapies for prostate health. Antev Limited, a UK-based pharmaceutical company, specializes in urology and BPH treatments and provides drugs for benign prostatic hypertrophy.

Major companies operating in the drugs for benign prostatic hypertrophy market are Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Pfizer Inc., Ipsen S.A., Novartis International AG, Bayer AG, Merck & Co. Inc., Endo Pharmaceuticals Inc., Impax Laboratories Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Eli Lilly and Company, Bausch Health Companies Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2025. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs For Benign Prostatic hypertrophy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drugs for benign prostatic hypertrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
• Subsegments:
• 1) By Alpha Blocker: Tamsulosin; Alfuzosin; Doxazosin; Terazosin; Silodosin
• 2) By 5-alpha Reductase Inhibitor: Finasteride; Dutasteride
• 3) By Phosphodiesterase-5 Inhibitor: Tadalafil; Sildenafil
• 4) By Other Types: Anticholinergics; Herbal Supplements (Saw Palmetto); Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
• Companies Mentioned: Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited; Sanofi S.A.; Pfizer Inc.; Ipsen S.A.; Novartis International AG; Bayer AG; Merck & Co. Inc.; Endo Pharmaceuticals Inc.; Impax Laboratories Inc.; Kissei Pharmaceutical Co. Ltd.; Abbott Laboratories; Eli Lilly and Company; Bausch Health Companies Inc.; Aurobindo Pharma Limited; Sun Pharmaceutical Industries Ltd.; Zydus Lifesciences Ltd.; Cipla Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Drugs For Benign Prostatic hypertrophy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Drugs For Benign Prostatic hypertrophy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Demand From Aging Male Population
  • 4.2.2 Increased Adoption Of Combination Therapies
  • 4.2.3 Growth Of Minimally Invasive Drug Treatments
  • 4.2.4 Expansion Of Generic Bph Drugs
  • 4.2.5 Growing Awareness Of Early Diagnosis

5. Drugs For Benign Prostatic hypertrophy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Urology Clinics
• 5.3 Retail Pharmacies
• 5.4 Online Pharmacies
• 5.5 Specialty Clinics

6. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drugs For Benign Prostatic hypertrophy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Drugs For Benign Prostatic hypertrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Drugs For Benign Prostatic hypertrophy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drugs For Benign Prostatic hypertrophy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drugs For Benign Prostatic hypertrophy Market Segmentation

• 9.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
• 9.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other End-Users
• 9.4. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
• 9.5. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Finasteride, Dutasteride
• 9.6. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tadalafil, Sildenafil
• 9.7. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

10. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

• 10.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

• 11.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drugs For Benign Prostatic hypertrophy Market

• 12.1. China Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drugs For Benign Prostatic hypertrophy Market

• 13.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drugs For Benign Prostatic hypertrophy Market

• 14.1. Japan Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drugs For Benign Prostatic hypertrophy Market

• 15.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drugs For Benign Prostatic hypertrophy Market

• 16.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drugs For Benign Prostatic hypertrophy Market

• 17.1. South Korea Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drugs For Benign Prostatic hypertrophy Market

• 18.1. Taiwan Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drugs For Benign Prostatic hypertrophy Market

• 19.1. South East Asia Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drugs For Benign Prostatic hypertrophy Market

• 20.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drugs For Benign Prostatic hypertrophy Market

• 21.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drugs For Benign Prostatic hypertrophy Market

• 22.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drugs For Benign Prostatic hypertrophy Market

• 23.1. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drugs For Benign Prostatic hypertrophy Market

• 24.1. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drugs For Benign Prostatic hypertrophy Market

• 25.1. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

• 26.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drugs For Benign Prostatic hypertrophy Market

• 27.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drugs For Benign Prostatic hypertrophy Market

• 28.1. North America Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drugs For Benign Prostatic hypertrophy Market

• 29.1. USA Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drugs For Benign Prostatic hypertrophy Market

• 30.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drugs For Benign Prostatic hypertrophy Market

• 31.1. South America Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drugs For Benign Prostatic hypertrophy Market

• 32.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drugs For Benign Prostatic hypertrophy Market

• 33.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drugs For Benign Prostatic hypertrophy Market

• 34.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drugs For Benign Prostatic hypertrophy Market Regulatory and Investment Landscape

36. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

• 36.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Drugs For Benign Prostatic hypertrophy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Drugs For Benign Prostatic hypertrophy Market Company Profiles
  • 36.3.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Drugs For Benign Prostatic hypertrophy Market Other Major And Innovative Companies

• Pfizer Inc., Ipsen S.A., Novartis International AG, Bayer AG, Merck & Co. Inc., Endo Pharmaceuticals Inc., Impax Laboratories Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Eli Lilly and Company, Bausch Health Companies Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd

38. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

40. Drugs For Benign Prostatic hypertrophy Market High Potential Countries, Segments and Strategies

• 40.1 Drugs For Benign Prostatic hypertrophy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Drugs For Benign Prostatic hypertrophy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Drugs For Benign Prostatic hypertrophy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer